Minimizing immunosuppression in liver transplant patients using everolimus

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the safety, efficacy, and tolerability of reducing and eventually withdrawing tacrolimus, an anti-rejection medication, in liver transplant recipients while using everolimus as a monotherapy to help preserve kidney function. A total of 270 participants will be randomized into two groups: one will undergo a stepwise reduction of tacrolimus and switch to everolimus, while the other will maintain a reduced dose of tacrolimus alongside everolimus. The study will last 18-20 months and will assess the outcomes of these treatment strategies in a multicenter setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Subject and/or legal guardian must be able to understand and provide informed consent
2. Adult (age greater than or equal to 18 years of age at time of informed consent) recipient of first liver transplant alone (de novo)
3. Estimated glomerular filtration rate \>=30 ml/min/1.73m\^2 at enrollment using the CKD-EPI 2021 equation
4. Treatment with tacrolimus therapy, with or without mycophenolic acid derivatives and/or corticosteroids
5. Female subjects of childbearing potential with negative pregnancy test upon study entry
6. All subjects of reproductive potential agreeing to use contraception for the duration of the study
7. Previous vaccination or documented immunity to varicella, measles, hepatitis B, pneumococcus, influenza, zoster (if \>=19 years old), and 2019-nCoV (COVID-19) as outlined in the DAIT Vaccination Guideline

Exclusion Criteria:

1. Inability or unwillingness of a participant to give written informed consent or comply with study protocol
2. Active unresolved systemic viral, bacterial, fungal, or parasitic infection requiring oral or intravenous anti-infective therapy
3. History of autoimmune liver disease including autoimmune hepatitis, primary sclerosing cholangitis, and/or primary biliary cirrhosis, or other contraindications to drug withdrawal
4. History of non-hepatic autoimmune disease requiring current or future systemic immunosuppressive therapy other than per study protocol
5. History post-transplant of Hepatic Artery Thrombosis or Portal Vein Thrombosis.
6. History of recurrent cirrhosis after liver transplantation.
7. Chronic use of systemic glucocorticoids, biological immunomodulatory therapy, or other immunosuppressive agents other than per study protocol
8. History of hepatitis B or C virus infection with detectable viral PCR at enrollment
9. History of prior organ transplantation (liver or other type)
10. History of \>= 2 biopsy-proven acute cellular rejection episodes of any severity, \>=1 moderate to severe rejection episode (histologically defined or requiring lymphodepletion therapy), or \>= 1 antibody- mediated rejection episode
11. Active treatment with any mTOR-inhibitor agent (everolimus, sirolimus)
12. Contraindication to treatment with everolimus (open wound or wound infection; urine protein: creatinine ratio \> 0.5 mg/mg; significant pancytopenia (any of the following: WBC \<1.5 K/uL or ANC \<1000 cells/uL or actively being treated with GCSF; Hb \<8.0; platelet count \<50K); serum triglycerides \> 1000 mg/dL; other per PI)
13. Abnormal liver function tests on study entry: Total Bilirubin (TB)\>1.5 mg/dL and Direct Bilirubin (DB) \>1.0 mg/dL, Alkaline Phosphatase (AP) \>200 U/L, and Alanine Aminotransaminase (ALT)\>60 U/L
14. Pregnant on enrollment or plan to become pregnant during the study period
15. Participation in another clinical trial that would interfere with this study's procedures and intervention:

    1. Use of investigational biologic or drug (within 8 weeks of study enrollment)
    2. Additional blood collection that would exceed research blood draw limits
    3. Any other procedure or intervention, in the investigator's opinion would interfere with this study
16. Received live attenuated vaccine(s) within 2 months of enrollment
17. Current, diagnosed, mental illness or current, diagnosed, or self-reported drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study
18. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

Where it's running

• Mayo Clinic Hospital Arizona (Site #: 71144)
  Phoenix, Arizona, United States Recruiting
• University of California, San Diego (Site #: 71179)
  San Diego, California, United States Recruiting
• University of California, San Francisco (Site #: 71108)
  San Francisco, California, United States Recruiting
• Northwestern University (Site #: 71110)
  Chicago, Illinois, United States Recruiting
• University of Michigan (Site #: 71154)
  Ann Arbor, Michigan, United States Recruiting
• Icahn School of Medicine at Mount Sinai (Site #: 71115)
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Justin Boike, MD — Northwestern University Feinberg School of Medicine: Transplantation
• Study coordinator: Tracia Debnam, MS
• Email: Tracia.debnam@nih.gov
• Phone: 301-761-7414

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Expanding HIV-positive donor livers for HIV-positive recipients

  This study tests whether liver transplants from HIV-positive donors to HIV-positive recipients are safe regarding opportunistic infections and cancer.

  Recruiting at 2 sites National Institute of Allergy and Infectious Diseases (NIAID) · Baltimore, Maryland and 1 other locations · NCT07778459

• Magnetic Resonance Cholangiopancreatography to help living liver donors and their recipients

  This study tests whether preoperative MRCP imaging can help select living liver donors and reduce biliary complications in recipients.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi · NCT07715500

• Reducing Immunosuppression by 50% in Young Liver Transplant Recipients

  This study tests whether cutting the immunosuppressive medicine by half in children with liver transplants is safe and effective.

  Recruiting at 7 sites Phase 2 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 10 other locations · NCT07549503

• Preoperative Carbohydrate Loading Before Liver Transplant

  This study tests whether drinking a carbohydrate beverage before anesthesia helps liver transplant patients recover faster.

  Recruiting Medical University of Warsaw · Warsaw · NCT07519057

• Doctor counseling plus smartphone apps to support healthy eating and activity after liver or kidney transplant

  This program tries whether doctor-delivered lifestyle counseling combined with two smartphone apps can help people aged 60 and older who had a liver or kidney transplant eat healthier and be more active.

  Recruiting IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, BO · NCT07305012

• Long-term health of children born to mothers who had a solid organ transplant

  This project will look for long-term heart, kidney, and immune system problems in people aged 16 and older who were born to mothers who had a kidney, liver, pancreas, heart, or lung transplant.

  Recruiting University Medical Center Groningen · Groningen, Provincie Groningen · NCT07291258

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.